Confirmation of mRNA fears

 Important statement from Dr. Joseph Fraiman, physician and clinical scientist. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Welcome to this Wednesday talk, June 12th.

Yesterday, we discussed the risks associated with the rapid development of mRNA vaccines for various conditions. Beyond the COVID vaccines, the FDA has approved the respiratory syncytial virus (RSV) mRNA vaccine, and an influenza mRNA vaccine is currently in phase three clinical trials.

Dr. Joseph Freeman, who we've previously interviewed, has issued a carefully worded statement on this matter, highlighting significant concerns about the mRNA vaccine program. Dr. Freeman was the lead author of a study that performed a secondary analysis of adverse events in phase three trials of Pfizer and Moderna vaccines. The study revealed a 16% higher risk of serious adverse events among mRNA vaccine recipients. This translates to about 1 in 800 recipients experiencing a serious adverse reaction.

These levels of adverse reactions are, in my view, outrageously high, and the vaccines should never have been approved. However, these findings only cover the acute effects because the trials did not run for a long period. They do not provide information about the long-term effects.

Let's now hear from Dr. Freeman. Listen carefully to his insights, and then we'll come back to discuss further.